Methyl Prednisolone: Brands, Price & Uses in Bangladesh

Methyl Prednisolone is a synthetic glucocorticoid (corticosteroid) used to reduce inflammation and suppress abnormal immune responses in a wide range of conditions. Its use spans several categories of evidence strength:

Established / Well-Recognized Uses

• Endocrine disorders: Primary or secondary adrenocortical insufficiency (usually combined with a mineralocorticoid), congenital adrenal hyperplasia, non-suppurative thyroiditis, hypercalcemia associated with cancer.
• Rheumatic disorders: As adjunctive therapy for short-term management of acute flares or exacerbations in rheumatoid arthritis (including juvenile rheumatoid arthritis), psoriatic arthritis, ankylosing spondylitis, acute gouty arthritis, and systemic lupus erythematosus.
• Severe allergic conditions: Control of severe or incapacitating allergic conditions such as seasonal or perennial allergic rhinitis, bronchial asthma, drug hypersensitivity reactions, serum sickness, and contact dermatitis, when conventional treatment is inadequate.
• Dermatologic diseases: Pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, severe psoriasis, severe seborrheic dermatitis.
• Respiratory diseases: Symptomatic sarcoidosis, Loeffler's syndrome, berylliosis, aspiration pneumonitis, acute exacerbations of chronic obstructive pulmonary disease, and as an adjunct in severe asthma exacerbations.
• Hematologic disorders: Acquired (autoimmune) hemolytic anemia, idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia, and selected cases of erythroblastopenia.
• Gastrointestinal diseases: To help patients tide over a critical period of disease in ulcerative colitis and Crohn's disease.
• Neurologic conditions: Acute exacerbations of multiple sclerosis; management of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.
• Neoplastic diseases: Palliative management of leukemias and lymphomas, as part of combination chemotherapy regimens.
• Ophthalmic diseases: Severe acute and chronic allergic and inflammatory conditions of the eye.
• Organ transplantation: Used in combination with other immunosuppressants to prevent and treat transplant rejection.

Off-Label Uses (commonly seen in practice)

• Adjunct in the management of severe COVID-19 pneumonia requiring supplemental oxygen (institution-specific protocols; use should follow current clinical guidance).
• Chemotherapy-induced nausea and vomiting prophylaxis (as part of an antiemetic combination regimen).

Because Methyl Prednisolone is used for so many different conditions, the specific dose, duration, and route (oral or injectable) must be individualized by a physician based on the diagnosis and severity of disease.

Dosage of Methyl Prednisolone is highly individualized based on the specific disease being treated, its severity, and the patient's response, rather than by fixed body-weight formulas alone. The lowest effective dose for the shortest duration necessary should be used.

Administration

• Oral tablets may be taken with or without food; taking with food can reduce gastrointestinal upset.
• For long-term therapy, an alternate-day dosing schedule (entire dose every other morning) may be used to reduce HPA-axis suppression and growth-retardation risk.
• Injectable forms are administered by a healthcare professional via IV, IM, intra-articular, or intralesional routes, depending on formulation and indication.
• Methyl Prednisolone should never be stopped abruptly after prolonged use (generally more than 2-3 weeks); the dose must be tapered gradually under medical supervision to avoid adrenal insufficiency and disease rebound.

Side effects of Methyl Prednisolone depend on dose and duration of use. Short courses are usually well tolerated; long-term or high-dose use carries greater risk.

Common

• Increased appetite, weight gain, fluid retention
• Insomnia, mood changes, nervousness
• Indigestion, nausea
• Elevated blood glucose
• Acne, increased sweating

Less Common but Serious

• Cushingoid features (moon face, central obesity, striae) with prolonged use
• Hypertension
• Osteoporosis and increased fracture risk with long-term use
• Peptic ulcer disease, GI bleeding or perforation
• Increased susceptibility to infections and masking of infection signs
• Posterior subcapsular cataracts, glaucoma, increased intraocular pressure
• Myopathy (muscle weakness), especially with prolonged use
• Psychiatric disturbances including euphoria, mood swings, depression, or psychosis
• Growth suppression in children with prolonged use
• Adrenal insufficiency/HPA-axis suppression, particularly after abrupt discontinuation of long-term therapy